Anidulafungin
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia
Trial Timeline
Jul 1, 2003 → Jun 1, 2004
NCT ID
NCT00056381About Anidulafungin
Anidulafungin is a phase 1/2 stage product being developed by Pfizer for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00056381. Target conditions include Neutropenia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01202253 | Pre-clinical | Completed |
| NCT00934934 | Phase 2 | Terminated |
| NCT01053884 | Phase 2 | Terminated |
| NCT00537329 | Phase 3 | Completed |
| NCT00056381 | Phase 1/2 | Completed |
Competing Products
20 competing products in Neutropenia